{
    "clinical_study": {
        "@rank": "75700", 
        "arm_group": [
            {
                "arm_group_label": "group with HBV reactivation", 
                "description": "group with hepatitis B virus reactivation"
            }, 
            {
                "arm_group_label": "group without HBV reactivation", 
                "description": "group without hepatitis B virus reactivation"
            }
        ], 
        "biospec_descr": {
            "textblock": "serum hepatitis B virus DNA"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This study is a retrospective analysis to explore the incidence of hepatitis B virus\n      reactivation after withdrawal of prophylactic antiviral therapy, the efficacy and safety of\n      chemotherapy, and overall survival rate in lymphoma patients with hepatitis B virus\n      infection."
        }, 
        "brief_title": "Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hepatitis", 
            "Hepatitis B", 
            "Lymphoma", 
            "Hematologic Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hematologic Diseases", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "All eligible patients will received prophylactic antiviral therapy during and within 6\n      months after chemotherapy in previous sudy. We did not assign specific interventions to the\n      subjects in this study. The primary endpoint of this study is the incidence of hepatitis B\n      virus reactivation after withdrawal of prophylactic antiviral therapy. The secondary\n      endpoints include the incidence of hepatitis flare related to hepatitis B virus reactivation\n      after withdrawal of prophylactic antiviral therapy, the tumor response rate, and overall\n      survival rate."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  treatment-naive patients with lymphoma\n\n          -  patients with a history of previous exposure to hepatitis B virus (HBV): HBsAg or\n             hepatitis B core antibody (anti-HBc) positive\n\n        Exclusion Criteria:\n\n          -  HBsAg and HBcAb negative"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "lymphoma patients with hepatitis B virus infection diagnosed in Peking University Cancer\n        Hospita"
            }
        }, 
        "enrollment": {
            "#text": "107", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108444", 
            "org_study_id": "PKU 2013-Autonomous-9"
        }, 
        "intervention_browse": {
            "mesh_term": "Antiviral Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hepatitis", 
            "hepatitis B", 
            "lymphoma", 
            "Hematologic Diseases"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100142"
                }, 
                "name": "Peking University Cancer Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients With Hepatitis B Virus Infection", 
        "overall_official": {
            "affiliation": "Beijing Cancer Hospital", 
            "last_name": "Jun Zhu, MD.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy", 
            "measure": "the incidence of hepatitis B virus delayed reactivation", 
            "safety_issue": "Yes", 
            "time_frame": "within one year after withdrawal of prophylactic antiviral therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108444"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Jun Zhu", 
            "investigator_title": "Chairman of lymphoma department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "the incidence of hepatitis B virus related hepatitis flare after withdrawal of prophylactic antiviral therapy", 
                "measure": "the incidence of hepatitis B virus related hepatitis flare", 
                "safety_issue": "Yes", 
                "time_frame": "within one year after withdrawal of prophylactic antiviral therapy"
            }, 
            {
                "measure": "Number of patients that achieve a tumor response", 
                "safety_issue": "Yes", 
                "time_frame": "within one year after withdrawal of prophylactic antiviral therapy"
            }, 
            {
                "measure": "overall survival rate", 
                "safety_issue": "Yes", 
                "time_frame": "within one year after withdrawal of prophylactic antiviral therapy"
            }
        ], 
        "source": "Peking University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2007", 
        "study_design": "Observational Model: Case Control, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}